Abstracts

Expand All

2020


2019


- Harshman LC, Puligandla M, Haas NB, Allaf M, Drake CG, McDermott DF, Signoretti S,


2018


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Sparano JA, Gray RJ, Wood WC, Makower DF, Lively TG, Saphner TJ, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer D, Bruisky A, Goetz MP,


2017


- Jonker DJ, Hotte SJ, Razak ARA, Renouf DJ, Lichty B, Bell JC, Powers J, Breitbach CJ,


35[Suppl; abstr TPS4136], 2017.


2016


• Lemieux J, Goss PE, Parulekar WR, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gelmon J, Strasser-Weippl K, Brundage MD, Whelan K, Tu D, Whelan TJ. Patient-reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. J Clin Oncol
34[Suppl; abstr LBA506]. 2016.


2015


CO.21). J Clin Oncol 33[suppl; abstr TPS3620].


• Parimi S, Karachiwala H, Lin Y, Monzon JG, Tam VC, Chen EX, Dancey J, Tang PA. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting. J Clin Oncol 33[suppl; abstr e17710].


• Penniment MG. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. J Clin Oncol 33[suppl 3; abstr 6]). 2015.


• Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, Hay JH, Ringash J, Liu


2014


• Bonomi M, Xu H, Laurie SA, Eisenhauer EA, Tu D, Pater JL, Seymour L, Bradbury PA. The association of treatment-emergent proteinuria (TEP) with baseline/treatment


trial. BSH 165[suppl1; abstr 124], 53-54. 2014.


and palliation of dysphagia in patients treated with radiotherapy (RT) or chemoradiotherapy (CRT) TROG 03.01 NCIC CTG ES.2. J Clin Oncol 32:5s[suppl; abstr 4009]. 2014.


- Moy B, Tu D, Richardson H, Maunsell E, Goss PE. NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction. J Clin Oncol 31[suppl; abstr 6557], 2013.


Renouf DJ, Parulekar W, Grigorieva J, Tu D, Moore MJ. Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. J Clin Oncol 31[suppl; abstr 4061], 2013.


2012


• Eisenhauer EA. Antiangiogenics in ovarian cancer: where are we now? Ann Oncol 23[ suppl 9, abstr 54IN], ix40-ix41, 2012.


• Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, Laberge F, Fenton D, Hirsh V, Zukin M, Stockler MR, Lee CW, Chen EX, Montenegro A, Ding K, Bradbury PA. A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously


- Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KI, Goss PE. Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. J Clin Oncol 30[suppl, abstr 524], 2012.


J Clin Oncol 30[suppl, abstr 7007], 2012.


- Steele R, Quirke P, Grieve R, Monson J, Couture J, de Metz C, Pugh C, Nichols L, Thompson LC, Sebag-Montefiore D, on behalf of all investigators MCTUL. Long Term Outcome After Anastomotic Leak and the Impact of Short Course Pre-Operative Radiotherapy - Data from the MRC CRO7 NCIC CO16 trial. 6th European Multidisciplinary Colorectal Cancer Congress, 2012.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

2011

- Chapman JW, O'Callaghan C, Hu N, Ding K, Yothers GA, Catalano PJ, Shi Q, Gray RG,


- Li X, Chen J, Wu Y, Tu D. Variable selections in the Cox proportional hazards model based on extended bayesian information criteria. 32nd Annual Conference of the International Society for Clinical Biostatistics, 2011.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


• Stiff PJ, Unger M, Cook J, Constine LS, Coban S, Shea TC, Winter JN, Miller TP,


2010


- Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28[18s, abstr CRA3507], 2010.


- Eisenhauer E. In search of intermediate endpoints. EORTC-NCI-AACR Symposium [abstr 29], 2010.


III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer. Ann Oncol 21[Suppl 8, abstr LBA4], viii2, 2010.


- Stewart AK, Trudel S, Bahlis NJ, White DJ, Sabry W, Belch A, Reiman T, Roy J, Shustik


• Cheang M, Chia SK, Tu D, Jiang S, Shepherd LE, Pritchard KI, Nielsen TO. Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol 27[15s], 2009.


• Chi KN, Hotte SJ, Yu E, Tu D, Eigl B, Tannock I, Saad F, North S, Powers J, Eisenhauer E. Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

- Craddock KJ, Buys TPH, Zhu CQ, Strumpf D, Pintillie M, Ding K, Seymour L, Jurisica I, Shepherd FA, Lam WL, Tsao M-S. High resolution genomic analysis of NSCLC reveals regions of DNA copy number gain that may be predictive of benefit from adjuvant chemotherapy. J Thoracic Oncol 4[9 suppl 1, abstr PD12.2.6], S580. 2009.


- Goss PE, Ingle JN, Martino S, Robert N, Muss H, Shepherd L, Pritchard KI, Livingston RB, Davidson N, Perez EA, Cameron D, Whelan T, Palmer M, Tu D. Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC


• Palmer M, Broxterman J, Shepherd L, Parulekar W. Tracking patients on an intergroup oncology study. It's a snap! Clinical Trials 6, 536, 2009.


• Pujade-Lauraine E, Mahner S, Kaern J, Gebski V, Heywood M, Vasey P, Reinhaller A, Vergote I, Pignata S, Ferrero A. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-


- Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Karapetis CS, Moore MJ, Zalcberg J, Simes


- Schell AJ, Young I, Hansen C, Chi KN, Taylor S. BRAF mutation status and growth factor receptor expression do not predict baseline factors or outcome in hormone refractory prostate carcinoma. United States and Canadian Academy of Pathology, 2008.


- Tan X, Takahara G, Tu D. Two-stage design for phase II cancer clinical trials with responses and early progression as coprimary endpoints. Statistical Society of Canada,
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

2008.


Part I, 437s, 2008.


2007


- Bramwell VHC, Pritchard KI, Tu D, Tonkin K, Vachhrajani H, Robert J, Arnold A, Vandenberg TA, O'Reilly SE, Graham B, Shepherd LE. How compliant are patients with


- Chi KN, Hotte SJ, Yu E, Eigl BJ, Tannock I, Saad F, North S, Powers J, Eisenhauer E. A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate...
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Tu D. Identification of patients who will benefit from a treatment based on their genetic profiles: Some examples and statistical issues. Workshop on Statistical Analysis of High-Throughput Genetic Data, 2007.


White D, Kovacs M, Belch A, Stewart K, Chen C, Rubin S, Macdonald D, Harnett E,

2006


O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andrulis I, Pritchard KL. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Research and Treatment 100[Suppl 1], S18, 2006.


Pollak M, Chapman JW, Shepherd L, Meng D, Richardson P, Wilson C, Orme B, Pritchard KL. Insulin resistance, estimated by serum C-peptide level, is associated with


2005

- Albain KS, Swann RS, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ, Gandara DR,


- Li D. Determinants of sample size and power in equivalence trials that compare binomial outcomes. Clinical Trials 2[Suppl 1], S59, 2005.
- Li D. Can more frequent regular group sequential tests help to make an earlier conclusion in clinical trials? A retrospective evaluation. Clinical Trials 2[Suppl 1], 2005.
- Messerschmidt T, Koski B. Integrating SOPs into a comprehensive website document management system. Clinical Trials 2[Suppl 1], S50, 2005.
- Miller KD, Wang M, Gralow J, Dickler M, Cobleigh MA, Perez EA, Shenkier TN,


- Tu D. Nonparametric estimate and confidence intervals for the hazard ratio based on censored data. Clinical Trials 2[Suppl 1], S36, 2005.

- Wong R, Paul N, Ding K, Brundage M, Fyles A, Pater J. Optimizing prophylaxis of
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2004

- Delaunoit TP, Krook J, Sargent DJ, Green E, Alberts SR, Fuchs C, Ramanathan R,

- Ding K. Point estimate following group sequential tests. ENAR Int Biometric Soc, 2004.
- Kristensen GB, Vergote I, Eisenhauer E, Baekelandt M, Stuart G, Aavall-Lundquist E,
Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


- Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields ALA, Carver G, Mayer RJ. Irinotecan plus fluorouracil/leucovorin versus fluorouracil/leucovorin...


2003


• Li D. A SAS macro to automate the covariance structure determination in repeated measures data analysis with mixed procedure. Pharmaceutical Industry SAS Users Group, 2003.


• Mazumdar M, Tu D. Efficiency of STRTA matched case-control studies with multiple controls per case in survival data setting. Controlled Clin Trials 24(3S), 112S, 2003.


Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


2002


- Hirte H, Siu L, Gelmon K, Britten C, Eisenhauer E, Fisher B, Ptaszynski M, Onetto N.


2001


• Douillard J, Petersen V, Shepherd F, Paz-Ares L, Arnold A, Tonato M, Ottaway J, Davis M, Van Vreckem A, Humphrey J, Seymour L. Randomised phase II study of BMS-275291 versus placebo in patients with stage IIIb or IV non small cell lung cancer


of tumor biopsy specimens from patients undergoing treatment with ZD1839. Clinical Cancer Research 7(suppl), 3708s, 2001.


inhibitor, NX 211, given on days 1, 2, 3 or days 1, 8 every 3 weeks to patients with advanced solid tumors. Proc.Am.Soc.Clin.Oncol. 19, 198a, 2000.


• Hirte H, Stewart D, Goel R, Chouinard E, Huan S, Elias I, Matthews S, Seymour L. NCIC CTG IND 113: Two phase I dose escalation pharmacokinetic studies of BAY 12-9566 in

Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


1998


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1997


- Bertelsen K, Kaern J, Simonsen E, Piccart M, Hoctin Boes G, Timmers P, Roy JA,


Roche K, Paul N, Walker H, Zee B, Smuck B, Hiatt M, Brittain M. Measuring workload of


---

**1996**


• Zee B. Phase II design for cancer clinical trials using multivariate endpoints. Biometric Society ENAR, 1996.


• Lofters C, Zee B. Adding 5 HT3 antagonists to dexamethasone after 24 hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 255, 1995.


• Lofters W, Zee B. Adding 5HT3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 339, 1995.


1994

- Mertens W, Eisenhauer E, Jolivet J, Ernst S, Moore M, Muldal A. Docetaxel in advanced


1993


- Paul N. The success of clinical trials depends on good communication. Joint meeting of EORTC SGDM and BODMA, 1993.


1992


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Pater J, Niezgoda H, Zee B. Validation of the EORTC-QLC -- a comparison with four other instruments in a heterogenous group of cancer patients. Ann.Oncol. 3(Suppl.5), 175, 1992.


---

1991


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1990

- Rusthoven J, Levin L, Eisenhauer E, Carmichael J. A phase I study of GM-CSF,


---

1989


- Palmer M, Pater J. Comparison of errors in body surface area and initial doses in five clinical trials (C0.2, C0.3, HD.4, MA.4, OV.8). Controlled Clin. Trials 10(3), 351, 1989.


1988


1987


1986

- Jolivet J, Landry L, Pinard MF, Eisenhauer E. Daily bolus x 9 trimetrexate: a phase I


- Wallenstein S, Patel HI, Willan A. Use of baseline values in the two period two treatment crossover design. Biometric Society ENAR, 1986.

1985


1984


1983


1981
